Gates Foundation adds $7.81M to Akagera's mRNA TB vaccine push
What's the deal? Akagera MedicinesDealroom has a profile for this one. Try Dealroom → has won a $7,806,414 grant expansion from the Gates FoundationDealroom has a profile for this one. Try Dealroom → to advance its dendritic cell-targeted mRNA vaccine against tuberculosis. The award brings the total committed under the grant to $9,791,826 and funds the steps needed to reach a first human trial.
What's the money for? The funding covers GMP manufacturing of clinical trial material and IND-enabling toxicology studies ahead of a regulatory filing and a Phase 1 trial. The clinical-stage biopharmaceutical company, majority owned by the Rwanda Social Security Board, develops lipid nanoparticle therapeutics and vaccines for infectious diseases.
How the vaccine works: Akagera's candidate pairs mRNA-encoded Mycobacterium tuberculosis antigens with a nanoparticle engineered to deliver its payload to dendritic cells, the immune system's most potent antigen-presenting cells. The aim is a strong, durable T-cell response at lower doses. Preclinical work, funded by an initial 2023 grant, showed robust immunogenicity in animal models.
Why now? Tuberculosis remains the world's deadliest infectious disease, killing more than a million people a year. BCG, the only licensed TB vaccine, is more than a century old and offers limited protection in the adolescents and adults who drive most transmission.
"This expanded support from the Gates Foundation marks the transition of our TB vaccine program from proof of concept to clinical readiness," said Daryl Drummond, co-founder and chief scientific officer.
What could go wrong? The program is still preclinical, so the grant is a development milestone, not evidence of efficacy or near-term availability. Akagera's separate lead therapeutic, AKG-100, reported positive first-in-human data in July 2026.
The signal: The award ranks in the 94th percentile by size among health grants in the US, underlining its scale. It arrives amid renewed momentum in TB vaccine development—M72/AS01E is in a 20,000-person Phase 3 trial, and the World Health Organization counted 17 candidates in clinical pipelines as of August 2026—where Akagera's early-stage, African-owned approach adds a fresh strategy to a field short on late-stage options.
Read more: finance.yahoo.com
Image credit: Akagera Medicines